학술논문
Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study
Document Type
Article
Author
Source
In: European Urology . (European Urology, November 2023, 84(5):449-454)
Subject
Language
English
ISSN
18737560
03022838
03022838